JAK2 Blood Cancer Treatment with ZE74-0282
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new drug called ZE74-0282 in patients with a specific type of blood cancer caused by a JAK2 V617F mutation. The drug is designed to target and slow the growth of these cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with a JAK2 V617F-positive blood cancer (confirmed by lab test)
- Your liver, kidneys, and heart function are adequate based on blood tests and heart rhythm checks
- You have recovered from side effects of any previous cancer treatments (most side effects down to Grade 1 or better)
- You are not pregnant, breastfeeding, or planning to become pregnant during the study and for 4 months after treatment ends
- You do not have an active infection that requires IV antibiotics, HIV, hepatitis B, or hepatitis C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, PRT12396, for people with certain blood cancers (polycythemia vera or myelofibrosis) that have a specific JAK2 mutation. It aims to see if the drug is safe and starts to work against the disease.
This trial tests a combination of two drugs—gecacitinib (a JAK inhibitor) and pegylated interferon—to see if they work better together for people with polycythemia vera (PV), a blood cancer that causes too many red blood cells. The study is for patients who have not tried these specific treatments before and who have symptoms like high blood counts, weight loss, night sweats, or an enlarged spleen.
This trial tests a new drug, JNJ-90189892, for people with certain types of blood cancers (acute myeloid leukemia or higher-risk myelodysplastic neoplasms) that have come back or not responded to treatment. The goal is to see if the drug is safe and effective.
This trial tests whether the drug ropeginterferon can help people with a JAK2 gene mutation who have additional risk factors but do not yet have a blood cancer. The goal is to see if treatment can prevent blood clots, high blood counts, or other complications.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.